News | July 26, 2024
Laurus Labs posts Q1 FY25 consolidated PAT at Rs. 12.51 Cr
Laurus Labs has reported total income of Rs. 1,197.42 crores during the period ended June 30, 2024
Laurus Labs has reported total income of Rs. 1,197.42 crores during the period ended June 30, 2024
The inspection was concluded with two 483 observations
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The inspections concluded with no Form 483 observations or significant critical findings
Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Vimta Labs has reported total income of Rs. 82.44 crores during the period ended June 30, 2024
The inspection closed with five observations which were more of procedural changes with none of these related to data integrity
Subscribe To Our Newsletter & Stay Updated
